Published in:
Open Access
01-12-2012 | Research article
Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families
Authors:
Juana Fernández-Rodríguez, Francisco Quiles, Ignacio Blanco, Alex Teulé, Lídia Feliubadaló, Jesús del Valle, Mónica Salinas, Àngel Izquierdo, Esther Darder, Detlev Schindler, Gabriel Capellá, Joan Brunet, Conxi Lázaro, Miguel Angel Pujana
Published in:
BMC Cancer
|
Issue 1/2012
Login to get access
Abstract
Background
Genes that, when mutated, cause Fanconi anemia or greatly increase breast cancer risk encode for proteins that converge on a homology-directed DNA damage repair process. Mutations in the SLX4 gene, which encodes for a scaffold protein involved in the repair of interstrand cross-links, have recently been identified in unclassified Fanconi anemia patients. A mutation analysis of SLX4 in German or Byelorussian familial cases of breast cancer without detected mutations in BRCA1 or BRCA2 has been completed, with globally negative results.
Methods
The genomic region of SLX4, comprising all exons and exon-intron boundaries, was sequenced in 94 Spanish familial breast cancer cases that match a criterion indicating the potential presence of a highly-penetrant germline mutation, following exclusion of BRCA1 or BRCA2 mutations.
Results
This mutational analysis revealed extensive genetic variation of SLX4, with 21 novel single nucleotide variants; however, none could be linked to a clear alteration of the protein function. Nonetheless, genotyping 10 variants (nine novel, all missense amino acid changes) in a set of controls (138 women and 146 men) did not detect seven of them.
Conclusions
Overall, while the results of this study do not identify clearly pathogenic mutations of SLX4 contributing to breast cancer risk, further genetic analysis, combined with functional assays of the identified rare variants, may be warranted to conclusively assess the potential link with the disease.